Brainsway Ltd (BWAY)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $406.96M
Last updated: Nov 17, 2026 at 10:59 AM ET
Brainsway Ltd (BWAY) P/E Ratio & Valuation History
Brainsway (BWAY) trades at 27.8x trailing earnings and 3.4x sales. Its P/B of 2.7x is below its 5-year median of 3.5x. Its forward P/E is 13.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 105.9% higher over the next year. Its free cash flow yield is 4.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 27.8x |
| Forward P/E | 13.5x |
| Price to sales | 3.4x |
| Price to book | 2.7x |
| Price to FCF | 23.4x |
| PEG | N/A |
| FCF yield | 4.3% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 2.7x | 3.5x | N/A |
Valuation History
Over the 6 of the 7 year ends shown that have a P/S, its P/S ranged from 3.0x in 2022 to 11.2x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $9.51 | 76.8x | 11.2x | 5.4x |
| 2024 | $4.72 | 70.7x | N/A | 2.9x |
| 2023 | $3.24 | N/A | 8.4x | 2.6x |
| 2022 | $1.24 | N/A | 3.0x | 1.8x |
| 2021 | $3.85 | N/A | 5.4x | 2.2x |
| 2020 | $3.77 | N/A | 6.4x | 8.5x |
| 2019 | $4.88 | N/A | 4.9x | 9.0x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BWAY
What is BWAY's forward P/E ratio?
Brainsway has a forward P/E ratio of 13.5x.
Is BWAY stock overvalued?
GNG's valuation label for BWAY is Undervalued.
What is BWAY's price to sales ratio?
Brainsway has a price to sales ratio of 3.4x.
BWAY pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors